Search results for " pharmacy"

showing 10 items of 365 documents

Predictability of drug encapsulation and release from propylene carbonate/PLGA microparticles.

2020

Abstract Key parameters for microparticle-based parenteral depot formulation development are entrapment efficiency and sustained drug release, which both depend on the intermolecular affinity of the components. Here, partial solubility parameters were evaluated as descriptors for 21 drug substances and 3 polymers in propylene carbonate (PC). Out of these 21 drug substances, eight BCS class II substances (celecoxib, clotrimazole, erythromycin, ibuprofen, indomethacin, itraconazole, lopinavir and ritonavir) were encapsulated using PLGA (Poly(DL-lactide-co-glycolide)) as polymer matrix and PC as a polar aprotic solvent in order to assign microparticle properties to potential affinity-related i…

Drug CompoundingPharmaceutical Science02 engineering and technology030226 pharmacology & pharmacy03 medical and health scienceschemistry.chemical_compoundPropane0302 clinical medicinePolylactic Acid-Polyglycolic Acid CopolymermedicineLactic AcidMicroparticleSolubilityParticle SizeChemistry021001 nanoscience & nanotechnologyIbuprofenMicrospheresSolventHildebrand solubility parameterPLGAChemical engineeringPharmaceutical PreparationsSolubilityPropylene carbonate0210 nano-technologyGlass transitionPolyglycolic Acidmedicine.drugInternational journal of pharmaceutics
researchProduct

A survey on IVIVC/IVIVR development in the pharmaceutical industry – Past experience and current perspectives

2017

The present work aimed to describe the current status of IVIVC/IVIVR development in the pharmaceutical industry, focusing on the use and perception of specific approaches as well as successful and failed case studies. Two questionnaires have been distributed to 13 EFPIA partners of the Oral Biopharmaceutics Tools Initiative and to the Pharmacokinetics Working Party of the European Medicines Agency in order to capture the perspectives and experiences of industry scientists and agency members, respectively. Responses from ten companies and three European Agencies were received between May 21st 2014 and January 19th 2016. The majority of the companies acknowledged the importance of IVIVC/IVIVR…

Drug IndustryOperations researchPharmaceutical Science02 engineering and technologyModels Biological030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicineIVIVCSurveys and QuestionnairesDrug DiscoveryAgency (sociology)AnimalsHumansRelevance (law)MedicinePharmacokineticsMarketingPharmaceutical industryRate of returnFlexibility (engineering)business.industry021001 nanoscience & nanotechnologyDrug developmentPositive attitude0210 nano-technologybusinessEuropean Journal of Pharmaceutical Sciences
researchProduct

Stability of tacrolimus ophthalmic solution

2017

Purpose The stability of 0.3-mg/mL tacrolimus ophthalmic solution at different storage temperatures was studied. Methods A sterile ophthalmic solution of 0.3 mg/mL tacrolimus was prepared in triplicate under aseptic conditions by diluting tacrolimus in eye drops. Three aliquots of this solution were transferred into polypropylene bottles and stored at 25, 2–8, or −15 to −25 °C. Samples were collected immediately after preparation and at selected time points and assayed in triplicate using high-performance liquid chromatography (HPLC). Samples were also visually examined for macroscopic changes. The 0.3-mg/mL tacrolimus solution was also exposed to acidic treatment and heat to force its degr…

Drug Storagemedicine.medical_treatmentAdministration Ophthalmicchemical and pharmacologic phenomena030226 pharmacology & pharmacyHigh-performance liquid chromatographyTacrolimus03 medical and health sciences0302 clinical medicineDrug StabilitymedicineHumansChromatography High Pressure LiquidPharmacologyChromatographyChemistryHealth PolicyTemperatureEye dropTacrolimusPharmaceutical Solutionssurgical procedures operativeOphthalmic solutionsAnesthesia030221 ophthalmology & optometryAseptic processingOphthalmic SolutionsImmunosuppressive AgentsAmerican Journal of Health-System Pharmacy
researchProduct

Core-Shell Arginine-Containing Chitosan Microparticles for Enhanced Transcorneal Permeation of Drugs

2019

Chitosan oligosaccharide (C) was functionalized with L-arginine (A) and short hydrocarbon chains (C-8) to design an amphiphilic copolymer, henceforth CAC(8), leading to microparticles (MPs) consisting of an arginine-decorated hydrophilic shell and inner hydrophobic domains allowing the encapsulation of high amount hydrophobic drugs such as sorafenib tosylate (>10% w/w). L-arginine side chains were selected in order to impart the final MPs enhanced transcorneal penetration properties, thus overcoming the typical biological barriers which hamper the absorption of drugs upon topical ocular administration. The mucoadhesive properties and drug release profile of the CAC(8) MPs (CAC(8)-MPs) were …

Drug3003congenital hereditary and neonatal diseases and abnormalitiesArginineSwinemedia_common.quotation_subjectamphiphilic copolymerPharmaceutical ScienceL-arginineAdministration Ophthalmic02 engineering and technologyArginine030226 pharmacology & pharmacyCorneaChitosan03 medical and health scienceschemistry.chemical_compoundDrug Delivery Systems0302 clinical medicineMucoadhesionSide chainAnimalsskin and connective tissue diseasesProtein Kinase Inhibitorsmedia_commonMucin-3microparticlesDrug CarriersMucinnutritional and metabolic diseasesSorafenibPermeation021001 nanoscience & nanotechnologyCombinatorial chemistryBioavailabilityDrug LiberationmicroparticlechemistrySettore CHIM/09 - Farmaceutico Tecnologico Applicativoocular administrationchitosan0210 nano-technologymucoadhesion
researchProduct

3D-Printed Solid Dispersion Drug Products.

2019

With the well-known advantages of additive manufacturing methods such as three-dimensional (3D) printing in drug delivery, it is disappointing that only one product has been successful in achieving regulatory approval in the past few years. Further research and development is required in this area to introduce more 3D printed products into the market. Our study investigates the potential of fixed dose combination solid dispersion drug products generated via 3D printing. Two model drugs&mdash

Drug3d printedMaterials sciencemedia_common.quotation_subjecteducationPharmaceutical Science3D printing02 engineering and technology030226 pharmacology & pharmacyPolyvinyl alcoholArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineamorphous solid dispersionfixed dose combinationmedia_commonbusiness.industry3D printing021001 nanoscience & nanotechnologySolventpoor solubilitychemistryChemical engineeringDrug deliveryManufacturing methods0210 nano-technologybusinessDispersion (chemistry)additive manufacturingPharmaceutics
researchProduct

Prescription drug use during pregnancy in France: a study from the national health insurance permanent sample.

2017

International audience; PurposeTo provide an up-to-date account of drug prescription during pregnancy in France from 2011 to 2014 using the permanent sample of the French national computerized healthcare database and with a focus on recommended supplementations, fetotoxic drugs and teratogenic drugs.MethodsAll pregnancies identified by the International Classification of Diseases, 10th Revision codes list in the hospitalization database, lasting more than 9 weeks of amenorrhea and whose delivery occurred between 01/01/2011 and 12/31/2014, were included. Drugs delivered between the trimester before and until the end of the pregnancy were included. Drug exposure prevalence was calculated for …

DrugAdultPediatricsmedicine.medical_specialtypharmacoepidemiologyPrescription drugPrescription DrugsNational Health ProgramsEpidemiologymedia_common.quotation_subject[SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics030226 pharmacology & pharmacy03 medical and health sciencesYoung Adult0302 clinical medicinePregnancymedicineHumansPharmacology (medical)Medical prescriptionPregnancy Trimestersmedia_commonPregnancy030219 obstetrics & reproductive medicinebusiness.industrydrug recommendationsadministrative healthcare databasePharmacoepidemiologymedicine.diseaseDrug classTeratogensprescription medicationsAmenorrheaFemaleFrancePregnancy Trimestersmedicine.symptombusinessPharmacoepidemiology and drug safety
researchProduct

Long-Circulating Hyaluronan-Based Nanohydrogels as Carriers of Hydrophobic Drugs

2018

[EN] Nanohydrogels based on natural polymers, such as polysaccharides, are gaining interest as vehicles for therapeutic agents, as they can modify the pharmacokinetics and pharmacodynamics of the carried drugs. In this work, hyaluronan-riboflavin nanohydrogels were tested in vivo in healthy rats highlighting their lack of toxicity, even at high doses, and their different biodistribution with respect to that of native hyaluronan. They were also exploited as carriers of a hydrophobic model drug, the anti-inflammatory piroxicam, that was physically embedded within the nanohydrogels by an autoclave treatment. The nanoformulation was tested by intravenous administration showing an improvement of…

DrugBiodistributionmedia_common.quotation_subjectRiboflavinPharmaceutical Sciencelcsh:RS1-441Pharmacokinetic02 engineering and technologyPharmacologyPiroxicam030226 pharmacology & pharmacyArticleNanohydrogelsLong circulatinglcsh:Pharmacy and materia medica03 medical and health sciencesPiroxicam0302 clinical medicineBiodistributionPharmacokineticsIn vivomedicineHyaluronanbiodistribution; hyaluronan; hydrophobic drugs; nanohydrogels; pharmacokinetic; piroxicam; riboflavinmedia_commonChemistry021001 nanoscience & nanotechnologyHydrophobic drugsToxicityCirculation time0210 nano-technologymedicine.drug
researchProduct

Efficacy of budesonide-loaded mesoporous silica microparticles capped with a bulky azo derivative in rats with TNBS-induced colitis.

2019

Abstract A colon targeted drug delivery system for inflammatory bowel diseases (IBD), consisting in budesonide loaded mesoporous silica microparticles functionalized with a selective azo-molecular gate (M-Bud), has been evaluated for in vivo efficacy. Experimental colitis in male Wistar rats was induced by rectal instillation of 2,4,6-trinitrobenzenesulfonic acid (TNBS). M-Bud was orally administered to the rats as a suspension in water. Colon/body weight ratio, clinical activity score, and histological evaluation were used as inflammatory indices to measure the performance of the microparticles. The formulation was compared with a suspension prepared from the commercial drug Entocord®. Sta…

DrugBudesonideMalemedia_common.quotation_subjectPharmaceutical Science02 engineering and technologyPharmacology030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicineDrug Delivery SystemsIn vivomedicineAnimalsColitisBudesonideTnbs colitismedia_commonChemistryMesoporous silica021001 nanoscience & nanotechnologymedicine.diseaseColitisSilicon DioxideControlled releasedigestive system diseasesRatsTargeted drug deliveryTrinitrobenzenesulfonic Acid0210 nano-technologyAzo Compoundsmedicine.drugInternational journal of pharmaceutics
researchProduct

Controlled transdermal iontophoresis by ion-exchange fiber

2000

The objective of this study was to assess the transdermal delivery of drugs using iontophoresis with cation- and anion-exchange fibers as controlled drug delivery vehicles. Complexation of charged model drugs with the ion-exchange fibers was studied as a method to achieve controlled transdermal drug delivery. Drug release from the cation-exchange fiber into a physiological saline was dependent on the lipophilicity of the drug. The release rates of lipophilic tacrine and propranolol were significantly slower than that of hydrophilic nadolol. Permeation of tacrine across the skin was directly related to the iontophoretic current density and drug concentration used. Anion-exchange fiber was te…

DrugChemical PhenomenaSkin Absorptionmedia_common.quotation_subjectPharmaceutical Science02 engineering and technologyIn Vitro TechniquesPharmacologyAdministration Cutaneous030226 pharmacology & pharmacyDosage form03 medical and health scienceschemistry.chemical_compound0302 clinical medicineHumansFiberElectrodesSodium salicylateTransdermalmedia_commonMineral FibersActive ingredientChromatographyIontophoresisChemistry PhysicalIontophoresisModels Theoretical021001 nanoscience & nanotechnologyIon ExchangechemistryDrug deliveryTacrine0210 nano-technologyAlgorithmsJournal of Controlled Release
researchProduct

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Proguanil Hydrochloride

2018

Abstract Literature data relevant to the decision to waive in vivo bioequivalence testing for the approval of generic immediate release solid oral dosage forms of proguanil hydrochloride are reviewed. To elucidate the Biopharmaceutics Classification System (BCS) classification, experimental solubility and dissolution studies were also carried out. The antimalarial proguanil hydrochloride, effective via the parent compound proguanil and the metabolite cycloguanil, is not considered to be a narrow therapeutic index drug. Proguanil hydrochloride salt was shown to be highly soluble according to the U.S. Food and Drug Administration, World Health Organization, and European Medicines Agency guide…

DrugCycloguanilProguanilmedia_common.quotation_subjectProguanil HydrochlorideAdministration OralPharmaceutical SciencePharmacologyBioequivalence030226 pharmacology & pharmacyDosage formExcipientsAntimalarials03 medical and health sciences0302 clinical medicineparasitic diseasesAnimalsHumansMedicineRegulatory sciencemedia_commonDosage Formsbusiness.industryBiopharmaceutics Classification SystemMalariaProguanilSolubilityTherapeutic Equivalency030220 oncology & carcinogenesisbusinessmedicine.drugJournal of Pharmaceutical Sciences
researchProduct